HULUWA(SH:605199) Zhi Tong Cai Jing·2025-09-05 09:18Core Viewpoint - ST HuLuWa (605199.SH) has received the drug registration certificate for Cefdinir capsules from the National Medical Products Administration, indicating a significant regulatory approval for the company’s product line [1] Company Summary - The approved drug, Cefdinir, is a third-generation broad-spectrum cephalosporin antibiotic, effective against various bacterial strains including Staphylococcus, Streptococcus, and Escherichia coli [1] - Cefdinir is indicated for treating multiple infections such as pharyngitis, tonsillitis, acute bronchitis, pneumonia, otitis media, and urinary tract infections among others [1] - The approval signifies that the drug meets the technical requirements for quality and efficacy consistent with reference formulations, and it is considered to have passed the consistency evaluation for generic drug quality and efficacy [1] Industry Summary - The approval of Cefdinir aligns with the growing demand for effective antibiotics in the healthcare sector, particularly for treating bacterial infections [1] - The regulatory approval process highlights the importance of compliance with quality standards in the pharmaceutical industry, which can impact market competitiveness [1]